The grey area re trial completion has largely to do with the FDA hold duration (now lifted). Furthermore, one plausible reason for the unexercising of the options.
Quarterly progress out this month, if results are mirrored as you say it will have a dual effect as did the last.
That is, for some a hit and run (must love the tax department) and for others one step closer to commercialisation.
Luck to holders.
PTX Price at posting:
10.0¢ Sentiment: Hold Disclosure: Held
